OAM
NMTR

Oxford Asset Management’s 9 Meters Biopharma NMTR Stock Holding History

Oxford Asset Management’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-7,144
Closed -$330K – 2085
2018
Q4 		$330K Buy
+7,144
New +$529K 0.01% 1367

Other funds holding NMTR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Oxford Asset Management's NMTR Position: Q1 2019 in Review

Oxford Asset Management sold out of 9 Meters Biopharma (NMTR) in Q1 2019, closing a stake of 7,144 shares — an estimated $330K sold.

Oxford Asset Management first reported a position in NMTR in Q4 2018 and held it in 1 quarter. The position peaked at $330K in Q4 2018. 38 funds tracked by Wall St. Rank hold NMTR as of Q1 2019.

  • Oxford Asset Management reported no remaining 9 Meters Biopharma position as of Q1 2019 after selling out during the quarter.
  • Oxford Asset Management sold 7,144 9 Meters Biopharma shares in Q1 2019, an estimated $330K.
  • Oxford Asset Management first reported a position in 9 Meters Biopharma in Q4 2018 and held it in 1 quarter.
  • Oxford Asset Management's 9 Meters Biopharma position peaked at $330K in Q4 2018.
  • 38 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.